Literature DB >> 17620494

Magnetic resonance imaging predictors of cognition in mild cognitive impairment.

Laura A van de Pol1, Esther S C Korf, Wiesje M van der Flier, H Robert Brashear, Nick C Fox, Frederik Barkhof, Philip Scheltens.   

Abstract

OBJECTIVES: To describe magnetic resonance imaging characteristics in a large sample of subjects with mild cognitive impairment (MCI) and to investigate associations between these characteristics and cognition.
DESIGN: Cohort study.
SETTING: Baseline data of a randomized, double-blind, placebo-controlled clinical trial of galantamine in MCI. PATIENTS: Included in the study were 896 subjects with MCI (age [mean +/- SD], 70 +/- 9 years; 54% women) with available clinical and magnetic resonance imaging data. MAIN OUTCOME MEASURES: Neuropsychology: Alzheimer Disease Assessment Scale, cognitive subscale, MCI version, assessing global cognition; delayed recall on the New York University Paragraph Recall Test, assessing episodic memory; and Digit Symbol Substitution Test, assessing executive function. Neuroimaging: Medial Temporal Lobe Atrophy (MTA) Rating Scale (0-4) and Age-Related White Matter Changes Scale (0-30), assessing white matter hyperintensities (WMHs); and lacune counts.
RESULTS: Median MTA score was 2 (range, 0-4), and mean (+/- SD) Age-Related White Matter Changes Scale score 6.0 (+/- 4.7). Lacunes were present in 33% of subjects. In unadjusted models, increasing MTA and WMHs were associated with poorer performance on all cognitive tests, and lacunes with poorer performance on the Alzheimer Disease Assessment Scale, cognitive subscale, MCI version, and the Digit Symbol Substitution Test. In multivariable models, including magnetic resonance imaging measures simultaneously, MTA remained a predictor of cognition, whereas WMH had no independent predictive value. There was an interaction between MTA and lacunes: the strength of the association with the Digit Symbol Substitution Test increased with decreasing MTA.
CONCLUSIONS: Medial temporal lobe atrophy seems to be a more important predictor of cognition than small-vessel disease in MCI. Lacunes were associated with performance on the Digit Symbol Substitution Test, especially in subjects with milder MTA. Although WMHs were prevalent and associated with cognition in unadjusted analyses, there was no discernible association between WMHs and the cognitive measures in this study after adjustment for age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17620494     DOI: 10.1001/archneur.64.7.1023

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  15 in total

1.  High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study.

Authors:  Andrea L C Schneider; Andreea M Rawlings; A Richey Sharrett; Alvaro Alonso; Thomas H Mosley; Ron C Hoogeveen; Christie M Ballantyne; Rebecca F Gottesman; Elizabeth Selvin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

2.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

3.  Memory after silent stroke: hippocampus and infarcts both matter.

Authors:  S Blum; J A Luchsinger; J J Manly; N Schupf; Y Stern; T R Brown; C DeCarli; S A Small; R Mayeux; A M Brickman
Journal:  Neurology       Date:  2012-01-03       Impact factor: 9.910

4.  MIDAS: Regionally linear multivariate discriminative statistical mapping.

Authors:  Erdem Varol; Aristeidis Sotiras; Christos Davatzikos
Journal:  Neuroimage       Date:  2018-03-07       Impact factor: 6.556

5.  Default mode network integrity changes contribute to cognitive deficits in subcortical vascular cognitive impairment, no dementia.

Authors:  Qi Qin; Yi Tang; Xuejiao Dou; Yida Qu; Yi Xing; Jianwei Yang; Tianshu Chu; Yong Liu; Jianping Jia
Journal:  Brain Imaging Behav       Date:  2021-02       Impact factor: 3.978

6.  Predicting Alzheimer's disease: neuropsychological tests, self-reports, and informant reports of cognitive difficulties.

Authors:  Laura A Rabin; Cuiling Wang; Mindy J Katz; Carol A Derby; Herman Buschke; Richard B Lipton
Journal:  J Am Geriatr Soc       Date:  2012-06       Impact factor: 5.562

Review 7.  Current and future uses of neuroimaging for cognitively impaired patients.

Authors:  Gary W Small; Susan Y Bookheimer; Paul M Thompson; Greg M Cole; S-C Huang; Vladimir Kepe; Jorge R Barrio
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

Review 8.  Neuroimaging biomarkers of neurodegenerative diseases and dementia.

Authors:  Shannon L Risacher; Andrew J Saykin
Journal:  Semin Neurol       Date:  2013-11-14       Impact factor: 3.420

9.  The metabolic syndrome and cognitive decline in the Atherosclerosis Risk in Communities study (ARIC).

Authors:  Jennifer L Dearborn; David Knopman; A Richey Sharrett; Andrea L C Schneider; Clifford R Jack; Laura H Coker; Alvaro Alonso; Elizabeth Selvin; Thomas H Mosley; Lynne E Wagenknecht; Beverly G Windham; Rebecca F Gottesman
Journal:  Dement Geriatr Cogn Disord       Date:  2014-08-20       Impact factor: 2.959

10.  Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease.

Authors:  Davangere P Devanand; Xinhua Liu; Matthias H Tabert; Gnanavalli Pradhaban; Katrina Cuasay; Karen Bell; Mony J de Leon; Richard L Doty; Yaakov Stern; Gregory H Pelton
Journal:  Biol Psychiatry       Date:  2008-08-23       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.